The next application submission deadline for The PREVENT Cancer Preclinical Drug Development Program is September 8, 2015.
The PREVENT Program was created in 2011 to provide investigators with novel ideas for interventions aimed at cancer prevention access to the National Cancer Institute’s (NCI) contract resources. Intervention strategies of high interest to PREVENT include chemoprevention and immunoprevention. Current areas of focus are:
? Antiinflammatory approaches
? Immunoprevention
? Novel mechanisms
? Drug repurposing
? Reducing toxicity (dosing and combinations)
The PREVENT Program application will not directly lead to a grant or contract award; rather NCI may allocate various contract resources and expertise towards implementation and development of approved, scientifically meritorious projects.
Examples of resources available from PREVENT are:
? In vitro and in vivo preclinical pharmacology and efficacy studies
? Preclinical Investigational New Drug (IND)-directed GLP toxicology studies
? Identification and evaluation of intermediate biomarkers
? Scale-up cGMP and non-cGMP production of an investigational agent
? PK and PK-PD modeling to optimize dosing regimen
? Formulation optimization for enhanced bioavailability and clinical usefulness
? Analytical method development for investigational agents in bulk form and in biological fluids and tissues
? Stability testing for bulk and formulated material
? Regulatory support
? Other resources to support drug development
Applications are accepted twice per year (March and September) and subjected to peer-review.
Researchers in academia, government, and industry, nationally and internationally, are encouraged to apply.
PREVENT applications can be found at: http://prevention.cancer.gov/major-programs/prevent-cancer-preclinical/instructions-applying
For more information about the PREVENT Program, go to: http://prevention.cancer.gov/major-programs/prevent-cancer-preclinical
Questions about PREVENT can be sent to:
PREVENT Cancer Program
Division of Cancer Prevention
National Cancer Institute
National Institutes of Health
9609 Medical Center Dr., MSC 9787
Rockville, MD 20850
email: NCIPREVENT@mail.nih.gov
